Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, ...

The overall findings from the landmark FLOW trial confirmed the potential of glucagon-like peptide 1 (GLP-1) receptor ...

Similar kidney and cardiovascular outcomes are found with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Ozempic is not approved for use in weight loss, however, many people have been taking the drug for this purpose. Semaglutide was approved for weight loss purposes under another name—Wegovy—which has a ...

It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...